Tuesday, July 10, 2012

New pathways on PharmGKB: Sorafenib PK and PD

We have added two new pathways: Sorafenib PK and PD pathways to our pathway collections. 

Sorafenib (Nexavar, BAY 43-9006) is a cancer drug used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma.  It blocks tumor cell proliferation and angiogenesis by targeting various types of serine/threonine and receptor tyrosine kinases.  PharmGKB sorafenib PD pathway describes its mechanism of action and PK pathway depicts candidate genes mediating the metabolism, transport of sorafenib and possible drug-drug interactions.

View or download the pathways at Sorafenib PK and PD.

View all pathways at PharmGKB.